MedTrace Logo

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

NCT03126071 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-08-30

No results posted yet for this study

Summary

The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer

Conditions

  • Advanced Colorectal Cancer

Interventions

DRUG

Raltitrexed

Raltitrexed:3mg/m2,iv 15min,d1,q3w.

DRUG

Irinotecan

Irinotecan:250mg/m2,iv 90min,d1,q3w.

DRUG

Oxaliplatin

Oxaliplatin:130mg/m2,iv 120min,d1,q3w.

DRUG

Bevacizumab

Bevacizumab:75mg/kg,iv 30min,d1,q3w.

Sponsors & Collaborators

  • Jiangsu Cancer Institute & Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2022-08-15
Completion
2023-02-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03126071 on ClinicalTrials.gov